AstraZeneca expands Rilvegostomig lung cancer trial to 1,160 patients
The Phase 3 head-to-head against pembrolizumab now targets 1,160 first-line NSCLC patients, up from 878, as its completion date moves to November 2030.
Executive Summary
- AstraZeneca increased the enrollment target for its pivotal rilvegostomig trial in first-line lung cancer and pushed the trial's completion timeline out, both routine registry updates rather than signs of trouble.
- The trial is designed as a direct survival comparison against pembrolizumab, the checkpoint inhibitor that has defined first-line treatment for this cancer for years, meaning matching the standard of care is not enough to win.
- A larger, later-reading trial gives the study more statistical power to detect a survival difference, but it also pushes the decision-relevant data further into the future.
- Checkpoint-inhibitor trial activity in this target class has slowed relative to its earlier pace, even as the sponsor's own execution record in this receptor class remains strong.
The change
The trial, registered as NCT06627647 and known as ARTEMIDE-Lung03, is testing rilvegostomig, AstraZeneca's anti-PD-1/anti-TIGIT bispecific antibody, against pembrolizumab, both paired with platinum-based chemotherapy, in patients with locally advanced or metastatic non-squamous NSCLC whose tumors express PD-L1 at 1% or higher. The registry raised the enrollment target from 878 to 1,160 patients on July 14, 2026. That same record shows the primary completion date moving from May 10, 2029 to November 18, 2030, a shift logged on June 29, 2026. NCT06627647+1A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCJul 14, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
The co-primary endpoints are overall survival and progression-free survival, measured against pembrolizumab as the active comparator rather than placebo. Because pembrolizumab is already the first-line standard for PD-L1-positive non-squamous NSCLC, the trial's bar is not merely showing rilvegostomig works: it is showing rilvegostomig extends survival, or slows progression, beyond what pembrolizumab already delivers in the same population. The design randomizes patients 1:1 between the two regimens, both layered onto chemotherapy. NCT06627647A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647
Reading the operational signals
The enrollment increase runs in the routine range for a registrational Phase 3 study of this kind and is not a signal of trial distress on its own. The trial remains in Recruiting status, and its title and eligibility criteria were also updated in the same July 14, 2026 filing, broadening the staging language from Stage IV to Stage III B/C or IV disease. AstraZeneca's broader checkpoint-receptor portfolio has closed 97% of its trials in this receptor family across 29 prior studies, a completion track record that provides context for how the sponsor has historically executed trials in this class. NCT06627647A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647
The competitive field
Rilvegostomig sits in a target class, PD-1 and TIGIT, where AstraZeneca itself runs the largest active footprint by trial count and enrollment among PD-1-targeting sponsors, ahead of Merck's pembrolizumab program. Direct comparators in Phase 3 NSCLC trials against pembrolizumab-based regimens include Merck's own pembrolizumab-combination studies and AbbVie's livmoniplimab, both anchored to the same PD-1 mechanism class. Recent PD-1 trial activity, measured by trial volume, has fallen to roughly 16% of its level from prior years, a decline that reflects a target class that has matured past its period of fastest expansion rather than one still accelerating.
What the readout will settle
With no results yet posted for this trial and no completed Phase 3 precedent for rilvegostomig against pembrolizumab in this population, the eventual overall survival and progression-free survival readout will be the first data point testing whether a PD-1/TIGIT bispecific can beat, rather than match, the pembrolizumab benchmark in first-line non-squamous NSCLC. The now-larger enrollment base positions the trial to detect a smaller survival difference than the original 878-patient design would have supported. NCT06627647A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCNCT06627647
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.